|
1）Saito H, Matsushita T, Kojima T. Historical perspective and future direction on coagulation research. J Thromb Haemost. 2011; 9 (suppl.1): 352-63
|
|
|
|
2）Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther. 1998; 63: 519-28
|
|
|
|
|
|
3）DʼAndrea D, DʼAmbrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005; 105: 645-9
|
|
|
|
|
|
4）Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Eng J Med. 2005; 352: 2285-93
|
|
|
|
|
|
5）Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonistics? N Eng J Med. 2013; 369: 2345-6
|
|
|
|
|
|
6）Kimmel S, French B, Kasner S, et al. A pharmacogenetics versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013; 369: 2283-93
|
|
|
|
|
|
7）Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013; 369; 2294-303
|
|
|
|
|
|
8）Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012; 125: 1997-2005
|
|
|
|
|
|
9）van Schie RM, Wadelius MI, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial design. Pharmacogenomics. 2009; 10: 1687-95
|
|
|
|
|
|
10）Verhoef T, Ragia G, Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013; 369: 2304-12
|
|
|
|
|
|
11）Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 98: 155-62
|
|
|
|
|
|
12）Stangier J, Rathgen K, Sähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Oharmacol. 2007; 64: 292-303
|
|
|
|
|
|
13）Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinet. 2009; 48: 1-22
|
|
|
|
|
|
14）Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011; 31: 478-92
|
|
|
|
|
|
15）Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor Xa inhibitor. Drugs. 2011; 71: 1503-26
|
|
|
|
|
|
16）Ogawa S, Kotetsune Y, Yasaka M, et al. Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents. Circ J. 2011; 75: 1539-47
|
|
|
|
|
17）Connolly SJ, Ezekowitz MD, Yufuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
|
|
18）Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91
|
|
|
|
|
|
19）Hori M, Matsumoto M, Tanahashi E, et al. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. －J-ROCKET AF study－. Circ J. 2011; 76: 2104-11
|
|
|
|
|
|
20）Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92
|
|
|
|
|
|
21）Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-104
|
|
|
|
|
|
22）FDA Drug Safety Communications. FDA study of medicare patients finds risk lower for stroke and death but high for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. 05-13-2014
|
|
|
|
|
|
23）Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383: 955-62
|
|
|
|
|
|
24）Adcock DM, Gosselin R, Kitchen S, et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013; 139: 102-9
|
|
|
|
|
|
25）van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel reversible, oral thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103: 1116-27
|
|
|
|
|
|
26）Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107: 985-97
|
|
|
|
|
|
27）Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry. 1996; 35: 1904-10
|
|
|
|
|
|
28）Mani H, Hesse C, Stratmann G, et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013; 109: 127-36
|
|
|
|
|
|
29）Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012; 23: 138-43
|
|
|
|
|
|
30）Garcia D, Barrett YC, Ramacciotti E, et al. Laboratory assessment of the anticoagulant effects of the next generation of anticoagulants. J Thromb Haemost. 2013; 11: 245-52
|
|
|
|
|
|
31）Dinkelaar J, Patiwael S, Harenberg J, et al. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med. 2014; 52: 1615-23
|
|
|
|
|
|
32）Samama MM, Guinet C, LeFlem L. Do new oral anticoagulant require laboratory monitoring? The clinical point of view. Thromb Res. 2012; 130(suppl 1): s88-9
|
|
|
|
|
|
33）ten Cate H. New oral anticoagulant: discussion on monitoring and adherence should start now! Thromb J. 2013; 11: 1-5
|
|
|
|
|
|
34）Bauer KA. Pros and cons of new oral anticoagulant. Hematology Am Soc Hematol Educ Program. 2013; 2013: 464-70
|
|
|
|
|